Back to Search
Start Over
Prospective study of epigenetic alterations responsible for isolated hemihyperplasia/hemihypoplasia and their association with leg length discrepancy
- Source :
- Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-13 (2021), Orphanet Journal of Rare Diseases
- Publication Year :
- 2021
- Publisher :
- BMC, 2021.
-
Abstract
- BackgroundHemihyperplasia and hemihypoplasia result in leg length discrepancy (LLD) by causing skeletal asymmetry. Beckwith–Wiedemann syndrome (BWS) and Silver–Russell syndrome (SRS) are opposite growth-affecting disorders caused by opposite epigenetic alterations at the same chromosomal locus, 11p15, to induce hemihyperplasia and hemihypoplasia, respectively. Because of their somatic mosaicism, BWS and SRS show a wide spectrum of clinical phenotypes. We evaluated the underlying epigenetic alterations and potential epigenotype-phenotype correlations, focusing on LLD, in a group of individuals with isolated hemihyperplasia/hemihypoplasia.ResultsWe prospectively collected paired blood-tissue samples from 30 patients with isolated hemihyperplasia/hemihypoplasia who underwent surgery for LLD. Methylation-specific multiplex-ligation-dependent probe amplification assay (MS-MLPA) and bisulfite pyrosequencing for differentially methylated regions 1 and 2 (DMR1 and DMR2) on chromosome 11p15 were performed using the patient samples. Samples from patients showing no abnormalities in MS-MLPA or bisulfite pyrosequencing were analyzed by single nucleotide polymorphism (SNP) microarray andCDKN1CSanger sequencing. We introduced a metric named as the methylation difference, defined as the difference in DNA methylation levels between DMR1 and DMR2. The correlation between the methylation difference and the predicted LLD at skeletal maturity, calculated using a multiplier method, was evaluated. Predicted LLD was standardized for stature. Ten patients (33%) showed epigenetic alterations in MS-MLPA and bisulfite pyrosequencing. Of these, six and four patients had epigenetic alterations related to BWS and SRS, respectively. The clinical diagnosis of hemihyperplasia/hemihypoplasia was not compatible with the epigenetic alterations in four of these ten patients. No patients showed abnormalities in SNP array or theirCDKN1Csequences. The standardized predicted LLD was moderately correlated with the methylation difference using fat tissue (r = 0.53;p = 0.002) and skin tissue (r = 0.50;p = 0.005) in all patients.ConclusionsIsolated hemihyperplasia and hemihypoplasia can occur as a spectrum of BWS and SRS. Although the accurate differentiation between isolated hemihyperplasia and isolated hemihypoplasia is important in tumor surveillance planning, it is often difficult to clinically differentiate these two diseases without epigenetic tests. Epigenetic tests may play a role in the prediction of LLD, which would aid in treatment planning.
- Subjects :
- Oncology
medicine.medical_specialty
Hemihypoplasia
Beckwith–Wiedemann syndrome
Hemihyperplasia
Single-nucleotide polymorphism
Epigenesis, Genetic
symbols.namesake
Silver–Russell syndrome
Internal medicine
medicine
Humans
SNP
Pharmacology (medical)
Prospective Studies
Epigenetics
Genetics (clinical)
Sanger sequencing
Leg
Hyperplasia
business.industry
Research
General Medicine
DNA Methylation
medicine.disease
Silver-Russell Syndrome
Differentially methylated regions
Leg length discrepancy
DNA methylation
symbols
Medicine
Lateralized overgrowth
business
SNP array
Subjects
Details
- Language :
- English
- ISSN :
- 17501172
- Volume :
- 16
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Orphanet Journal of Rare Diseases
- Accession number :
- edsair.doi.dedup.....837173620480668d89a7557b6f2ec20e